Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

The first lawsuit, filed on Friday, claims Novo's bid breaches Pfizer's merger agreement and seeks to bypass antitrust review ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

WILMINGTON, DEL. (Reuters) -A Delaware judge said on Tuesday she did not see in a preliminary evaluation the need to involve ...

Pfizer raised its full-year profit forecast for the second consecutive quarter and reported a higher-than-expected ...

Pfizer’s lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by ...

Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a ...

Novo Nordisk's new CEO said he was confident in the company's pipeline of obesity drugs, but that buying Metsera would allow ...

Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera, but said ...